Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Research & Development (2023 - 2025)

Historic Research & Development for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $27.9 million.

  • CG Oncology's Research & Development rose 4210.58% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.5 million, marking a year-over-year increase of 5840.15%. This contributed to the annual value of $82.1 million for FY2024, which is 7945.01% up from last year.
  • CG Oncology's Research & Development amounted to $27.9 million in Q3 2025, which was up 4210.58% from $31.3 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Research & Development peaked at $31.3 million during Q2 2025, and registered a low of $7.8 million during Q1 2023.
  • In the last 3 years, CG Oncology's Research & Development had a median value of $18.5 million in 2024 and averaged $19.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 11945.93% in 2024, then soared by 4210.58% in 2025.
  • CG Oncology's Research & Development (Quarter) stood at $16.3 million in 2023, then soared by 64.01% to $26.8 million in 2024, then rose by 4.04% to $27.9 million in 2025.
  • Its Research & Development stands at $27.9 million for Q3 2025, versus $31.3 million for Q2 2025 and $27.5 million for Q1 2025.